[Report] Antihypertensives Commercial Insight Market Research, Trends, Analysis TOC

CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the hypertension market
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition and overview for this report
- Hypertension
  - Disease overview
  - Epidemiology
  - Treatment options; the antihypertensive drug classes
    - Drugs that inhibit the renin-angiotensin system (RAS)
    - Drugs that do not inhibit the renin-angiotensin system (RAS)
    - Other classes of antihypertensive drugs
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the antihypertensives market
  - The global market: overview, opportunities and threats
    - Overview
    - National markets
    - The global movers and shakers
    - Global opportunities
    - Global threats
  - US market: overview, opportunities and threats
    - Overview
    - US market issues
  - Japan: overview, opportunities and threats
    - Overview
    - Japanese market issues
  - European Union: overview, opportunities and threats
    - Overview
    - EU market issues
CHAPTER 4 FORECAST ANALYSIS
- Assumptions and events
  - Ongoing trends
    - Increasing market size
    - Increasing use of fixed-dose combinations
    - Trial results
  - New product launches
    - S-amlodipine
    - SPP100 (aliskiren)
    - Caduet
  - Patent issues
    - ARB patent expiries
    - CCB patent expiries
    - Beta-blocker patent expiries
    - ACE inhibitor patent expiries
    - Other patent expiries
  - Additional indications
    - Irbesartan gains congestive heart failure indication
    - Valsartan gains additional diabetes indication
- Methodology
- Forecasts
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Introduction
  - Case study 1
    - Novartis and the "renin revolution"
  - Case study 2
    - Clinical trial data and the potential to change prescribing habits
  - Case study 3
    - EU healthcare reforms: a tale of two countries
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Global hypertension market data
  - Major brand facts
    - C7 BBs
    - C8 CCBs
    - C9 ACEIs
    - C9 ARBs
  - Anatomical Therapeutic Chemical (ATC) classification
APPENDIX B
- Bibliography
  - Hypertension management guidelines
    - JNC 7
    - ESH/ESC
    - WHO/ISH
    - BHS-IV
  - References
- Report methodology
  - General
  - Japan sales data
  - Key opinion leaders
  - About Datamonitor
  - About Datamonitor Healthcare
  - About the Cardiovascular Disease analysis team
- Disclaimer
- Glossary
APPENDIX C - MARKET FORECAST DATA
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- M5EU forecasts
- Global forecasts
- List of Tables
  - Table 1: A comparison of the various forms of hypertension recognized by three of the key hypertension guidelines
  - Table 2: Sales, sales growth and market share of the ARBs in the seven major markets, 2005
  - Table 3: Sales, growth and market share for antihypertensive drug classes in the seven major markets, 2003-04
  - Table 4: ARB sales in the seven major markets, 2004
  - Table 5: Prevalence of obesity in the seven major markets by age (000s), 2003
  - Table 6: US sales and growth of antihypertensive drug classes
  - Table 7: Japan sales and growth of antihypertensive drug classes
  - Table 8: M5EU sales and growth of antihypertensive drug classes
  - Table 9: Country-specific sales for antihypertensive drugs in the five major European countries
  - Table 10: Patent expiry dates used in forecasting the antihypertensive market across the seven major markets
  - Table 11: Comparison of hypertension levels from the BHSIV guidelines and the GMS contract QOF
  - Table 12: Coreg: key facts
  - Table 13: Toprol-XL: key facts
  - Table 14: Tenormin; key facts
  - Table 15: Inderal: key facts
  - Table 16: Norvasc: key facts
  - Table 17: Plendil: key facts
  - Table 18: Cardizem LA: key facts
  - Table 19: Adalat: key facts
  - Table 20: Altace: key facts
  - Table 21: Aceon: key facts
  - Table 22: Accupro: key facts
  - Table 23: Atacand; key facts
  - Table 24: Teveten: key facts
  - Table 25: Avapro: key facts
  - Table 26: Cozaar: key facts
  - Table 27: Benicar: key facts
  - Table 28: Micardis: key facts
  - Table 29: Diovan: key facts
  - Table 30: Antihypertensive classifications
  - Table 31: US: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 32: Japan: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 33: France: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 34: Germany: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 35: Italy: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 36: Spain: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 37: UK: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 38: M5EU: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
  - Table 39: Global: antihypertensive sales forecasts ($m), 2006-14, with CAGR between 2004-14 (%)
- List of Figures
  - Figure 1: Prevalence of hypertension broken down by age, 2004-15
  - Figure 2: The renin-angiotensin system
  - Figure 3: Angiotensin II is a cardiovascular risk factor with direct tissue effects
  - Figure 4: Recommendations for the combining of blood pressure lowering drugs (AB/CD rule) (adapted from Williams et al., 2004)
  - Figure 5: Pharmaceutical sales in the seven major markets, 2004
  - Figure 6: Market share by antihypertensive class, 2001 and 2004 in the seven major markets
  - Figure 7: Sales, growth and market share for antihypertensive drug classes in the seven major markets, 2003-04
  - Figure 8: Global sales values for the antihypertensive classes, 2001-04
  - Figure 9: Average ex-manufacturer prices of the leading brands of each antihypertensive class across all country markets, 2001-04
  - Figure 10: Share of antihypertensives market represented by each of the seven major markets, 2004
  - Figure 11: Proportion of population aged 20-39 years, 2004 and 2015, and prevalence of hypertension in this age group in the seven major markets, 2004
  - Figure 12: Proportion of population aged 40-59 years, 2004 and 2015, and prevalence of hypertension in this age group in the seven major markets, 2004
  - Figure 13: Proportion of population aged 60-79 years, 2004 and 2015, and prevalence of hypertension in this age group in the seven major markets, 2004
  - Figure 14: Annual US sales of antihypertensive drug classes, 2001-04
  - Figure 15: JNC6 and JNC7 compared; classification of blood pressure levels
  - Figure 16: Compelling indications for individual drug classes
  - Figure 17: Annual Japanese sales of antihypertensive drug classes, 2001-04
  - Figure 18: Annual M5EU sales of antihypertensive drug classes, 2001-04
  - Figure 19: Unlike the ARBs, SPP100 produces significant Reductions in plasma renin activity (PRA)
  - Figure 20: Clinical development activity with SPP100 (aliskiren), 2005
  - Figure 21: Speedel's Phase II study on SPP100
  - Figure 22: Novartis's Phase IIb study on SPP100 (Study 2201)
  - Figure 23: Systolic blood pressure (SBP) reductions during Novartis's SPP100 plus Diovan study (Study 2203)
  - Figure 24: Diastolic blood pressure (DBP) reductions during Novartis's SPP100 plus Diovan study (Study 2203)
  - Figure 25: SPP100; building the brand & differentiating it in the market
  - Figure 26: ASCOT study design
  - Figure 27: ASCOT trial profile
  - Figure 28: Domestic and Foreign Sales of German Pharmaceutical Companies
  - Figure 29: QOF eleven clinical areas (points)
  - Figure 30: The impact of healthcare reforms in Germany on sales growth within the antihypertensive drug market
  - Figure 31: The impact of healthcare reforms in the UK on sales growth within the antihypertensive drug market

Commercial Insight: Antihypertensives - Two Years to Shape the Market?

Table of Contents